BMBrenna McCormack

Brenna McCormack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brenna McCormack has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of epiretinal membranes with disability in people with multiple sclerosis

    by Ting-Yi Lin, Anna Bacchetti, Brenna McCormack, Hussein Moussa, Jonathan D Krett, Omar Ezzedin, Gabriel Otero-Duran, Nicole Pellegrini, Madeline Inserra, Scott D Newsome, et al.

    Background: Epiretinal membranes (ERMs) consist of glial and fibrocellular tissue, potentially arising from pathologic microgliosis, macrogliosis, and/or retinal pigment epithelium (RPE) cell migration. The clinical relevance of ERMs in people with multiple sclerosis (PwMS) remains largely unstudied. Objectives: To investigate ERM prevalence and their associations with retinal layer thicknesses and disability measures in PwMS. Methods: PwMS exhibiting ERMs (ERM+) were matched 1:1 with PwMS without ERMs (ERM−) by optic neuritis (ON) history, multiple sclerosis (MS) subtype, age, sex, and race. Disability assessments included high-contrast/low-contrast letter acuity (HC-/LCLA), Expanded Disability Status Scale (EDSS), walking speed test (WST), manual dexterity test (MDT), and processing speed test (PST) scores. Results: Among 1264 participants screened (1120 PwMS and 144 healthy controls [HCs]), ERMs were observed in 206 PwMS (18.4%) and 17 HCs (11.8%). ERM+ PwMS exhibited higher EDSS (1.0 ± 0.3, p = 0.002), longer WST (0.8 ± 0.2 seconds, p < 0.001), longer MDT (2.2 ± 0.5 seconds, p < 0.001), lower PST (−3.0 ± 1.4, p = 0.08), lower LCLA (−4.2 ± 1.1 letters, p < 0.001), and lower ganglion cell-inner plexiform layer (−1.8 ± 0.8 µm, p = 0.03), inner nuclear layer (−0.8 ± 0.3 µm, p = 0.01), outer nuclear layer (−1.6 ± 0.6 µm, p = 0.01), and RPE (−0.5 ± 0.1 µm, p < 0.001) thicknesses. Higher ERM stage correlated with greater disability. Conclusion: ERMs may identify a distinct MS phenotype, potentially characterized by pathological microglial and/or macroglial activity. ERMs may be a marker of similar global processes throughout the central nervous system that potentially contribute to greater overall disability.


  • Open Access

    Effect of ocrelizumab on rates of retinal atrophy in relapsing multiple sclerosis

    by Brenna McCormack, Anna Bacchetti, Ting-Yi Lin, Giulia S. Moretti, Angeliki Filippatou, Georgios Gakis, Martin Maurice O’DOnnell, Clare McGarvey Lambert, Nathanael J. Lee, Kaitlyn Ecoff, et al.

    Background: Ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis (MS). The effect of ocrelizumab, an anti-CD20 monoclonal antibody and highly-effective disease modifying therapy (DMT), on rates of GCIPL atrophy in people with MS remains understudied. Objectives: To assess if ocrelizumab attenuates retinal atrophy rates, particularly GCIPL atrophy, and change in clinical measures in people with relapsing MS (PwRMS), and how this compares to natalizumab (another highly-effective DMT), as well as the related anti-CD20 therapy rituximab. Methods: PwRMS receiving ocrelizumab, natalizumab, or rituximab, untreated people with progressive MS (PwPMS), and healthy controls underwent Cirrus HD-OCT, 100% and 2.5%-contrast letter acuity (LA) assessments longitudinally. MS participants underwent Expanded Disability Status Scale (EDSS) assessments. Statistical analyses used linear mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between DMT initiation and OCT monitoring; accounting for within-subject, inter-eye correlations. Results: In ocrelizumab-treated PwRMS, GCIPL atrophy rate was −0.15 µm/year (SE = 0.03, p < 0.001, n = 88 [168 eyes]), similar to GCIPL atrophy in natalizumab- or rituximab-treated PwRMS, and healthy controls, although slower than in untreated PwPMS (−0.35 µm/year, SE = 0.04, p < 0.001, n = 40 [78 eyes]). EDSS and LA scores remained stable in ocrelizumab-treated PwRMS, and similar to natalizumab- or rituximab-treated PwRMS. Conclusion: GCIPL atrophy is attenuated and clinical function relatively stable in PwRMS treated with ocrelizumab.

  • Open Access

    Retinal atrophy in multiple sclerosis is similar with extended versus standard interval natalizumab therapy

    by Brenna McCormack, Omar Ezzedin, Ting-Yi Lin, Anna Bacchetti, Giulia S. Moretti, Ernest Lievers, Ananya Gulati, Simidele Davis, Gabriel Otero-Duran, Devon J. Bonair, et al.

    Background: Retinal ganglion cell + inner plexiform layer (GCIPL) atrophy reflects global neurodegeneration and disability in multiple sclerosis. Extended interval dosing (EID; every 5–8 weeks) natalizumab reduces progressive multifocal leukoencephalopathy risk in people with relapsing–remitting multiple sclerosis (PwRRMS) versus standard interval dosing (SID; every 4 weeks). Objectives: To assess if EID versus SID natalizumab differentially impacts GCIPL atrophy, other retinal layer (peripapillary retinal nerve fiber layer (pRNFL), inner nuclear layer (INL), and outer nuclear layer (ONL)) atrophy, and/or clinical outcomes in PwRRMS. Methods: PwRRMS underwent longitudinal Cirrus high-definition optical coherence tomography (OCT), expanded disability status scale (EDSS), 100% and 2.5% contrast letter-acuity (LA) assessments. Analyses utilized mixed-effects regression models adjusting for age, sex, race, disease duration, optic neuritis history, and interval between treatment initiation and OCT monitoring, accounting for within-subject, inter-eye correlations. Results: GCIPL and pRNFL atrophy rates were not significantly different between EID ( n = 22) and SID ( n = 109) natalizumab ( p = 0.48, p = 0.24). INL and ONL atrophy were faster with EID versus SID natalizumab ( p = 0.02, p < 0.001). Age was higher (44.8 vs. 40.1 years, p = 0.03) and disease duration longer (15.2 vs. 8.4 years, p < 0.001) in the EID natalizumab cohort. Annual EDSS and 100% and 2.5% LA changes were similar between cohorts. Conclusion: We detected no significant difference in GCIPL or pRNFL atrophy, or clinical outcomes, between EID and SID natalizumab. Faster INL and ONL atrophy may relate to cohort demographic differences.

  • Open Access

    Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neuritis Associated With NMOSD, MOGAD, and MS

    by Angeliki G. Filippatou, Georgios Gakis, Anna Bacchetti, Anna Kim, Yana Said, Brenna McCormack, Ting-Yi Lin, Adam Didouchevski, Nicole Pellegrini, Kathryn C. Fitzgerald, et al.

    Background and ObjectivesOptic neuritis (ON) is a common manifestation of multiple sclerosis (MS), aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD), and myelin oligo...


  • Influence of OSCAR-IB criteria on test–retest reliability of Spectralis SD-OCT retinal thickness measurements in people with Multiple Sclerosis

    by Anna Bacchetti, Brenna McCormack, Ting-Yi Lin, Angeliki G Filippatou, Georgios Gakis, Nicole Pellegrini, Evan Kinder, Ananya Gulati, Ernest Lievers, Gabriel Otero-Duran, et al.

    Background: Optical coherence tomography (OCT) enables evaluation of inter-eye differences (IEDs) in peri-papillary retinal nerve fiber layer (pRNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses to identify unilateral optic nerve involvement (UONI), included in the 2024 revised McDonald diagnostic criteria for multiple sclerosis (MS). Objectives: To evaluate pRNFL and GCIPL thickness test–retest reliability in scans fulfilling (SFO) versus not fulfilling (SNFO) OSCAR-IB criteria in people with MS using Spectralis SD-OCT. Methods: From 164 participants, two scans per eye per protocol (optic nerve head: pRNFL; macular volume: GCIPL) were obtained with Spectralis SD-OCT and classified as SFO or SNFO. Intra-visit intraclass correlation coefficients (ICCs) and coefficients of variation (COVs) quantified reproducibility. Results: pRNFL thicknesses from SNFO exhibited lower reliability ( n = 72, ICC = 0.827, COV = 3.38%), than from SFO ( n = 216, ICC = 0.991, COV = 1.14%). GCIPL thicknesses demonstrated excellent reliability from both SFO ( n = 199, ICC = 0.997, COV = 0.53%) and SNFO ( n = 97, ICC = 0.990, COV = 0.83%). Algorithm failure and low signal strength most affected pRNFL (COV = 7.72%) and GCIPL (COV = 3.34%) reproducibility, respectively. Conclusions: OSCAR-IB violations negligibly affected GCIPL reliability, although reduced pRNFL reliability, supporting quality control to avoid erroneous UONI, and suggesting that GCIPL measures may be more robust than pRNFL measures with Spectralis SD-OCT, in contrast to prior Cirrus HD-OCT studies.


  • Open Access

    Influence of OSCAR-IB Criteria on Test-Retest Reliability of Cirrus HD-OCT Retinal Thickness Measurements in People With Multiple Sclerosis

    by Anna Bacchetti, Ting-Yi Lin, Brenna McCormack, Omar Ezzedin, Rozita Doosti, Gelareh Ahmadi, Nicole Pellegrini, Evan Johnson, Simidele Davis, Elle Lawrence, et al.

    Optical coherence tomography (OCT) allows evaluation of inter-eye differences (IEDs) in macular ganglion cell-inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thicknesses to identify unilateral optic nerve involvement (UONI). UONI supports dissemination in space (DIS) as part of the 2024 revised McDonald diagnostic criteria for multiple sclerosis (MS). The OSCAR-IB quality control (QC) criteria identify suboptimal-quality OCT scans, which could potentially result in false-positive or false-negative UONI identification. We aimed to determine the influence of scans fulfilling OSCAR-IB criteria (SFO) and not fulfilling (SNFO) on test-retest reliability of pRNFL and GCIPL thicknesses/IEDs, with a commonly used OCT platform (Cirrus HD-OCT). A total of 509 participants, including 397 people with MS, underwent Cirrus HD-OCT, with acquisition of 2 macular and optic disc scans per eye. Each scan was classified as either SFO or SNFO. There were no clinical or demographic exclusions in order to reflect a real-world clinical setting. Reproducibility was evaluated with intravisit intraclass correlation coefficients (ICCs) and coefficients of variation (COVs). IED consistency was assessed with difference-in-differences (DiDs) and probabilities of agreement (POA) for specific IED thresholds (GCIPL </≥4; pRNFL </≥6 μm). A total of 1,143 macular scan pairs (1,100 SFO and 42 SNFO) for GCIPL and 1,108 optic disc scan pairs (1,003 SFO and 105 SNFO) for pRNFL were analyzed. SFO demonstrated superior reliability, as compared to SNFO for GCIPL (SFO: ICC = 0.998, COV = 0.40%; SNFO: ICC 0.353, COV 10.14%) and pRNFL (SFO: ICC = 0.989, COV = 1.18%; SNFO: ICC = 0.852, COV = 3.94%) thicknesses. DiDs were lower for SFO (GCIPL 0.64 ± 0.67 μm, pRNFL: 2.00 ± 1.72 μm), as compared to SNFO (GCIPL: 10.17 ± 13.87 μm, pRNFL: 4.78 ± 5.51 μm). POA of IED thresholds (GCIPL: </≥4; pRNFL: </≥6 μm) was higher for SFO than for SNFO (GCIPL: 95.58% vs 47.83%; pRNFL: 86.89% vs 71.67%). GCIPL and pRNFL thicknesses/IEDs demonstrated markedly inferior reliability in SNFO, relative to SFO. Failure to fulfill OSCAR-IB criteria influenced pRNFL measurements and, in particular, GCIPL measurements, highlighting the importance of thorough QC in the interpretation of OCT to correctly identify UONI and accurately support DIS for the diagnosis of MS.


  • Open Access

    Test–retest reliability of Cirrus HD-optical coherence tomography retinal layer thickness measurements in people with multiple sclerosis

    by Anna Bacchetti, Brenna McCormack, Ting-Yi Lin, Rozita Doosti, Gelareh Ahmadi, Omar Ezzedin, Nicole Pellegrini, Evan Johnson, Anna Kim, Gabriel Otero-Duran, et al.

    Background: Optical coherence tomography (OCT) allows evaluation of inter-eye differences (IEDs) in peri-papillary retinal nerve fiber layer (pRNFL) and macular ganglion cell-inner plexiform layer (GCIPL) thicknesses to identify unilateral optic nerve involvement (UONI), which is included in the 2024 revised McDonald diagnostic criteria for multiple sclerosis (MS). Objectives: To evaluate the test–retest reliability of pRNFL and GCIPL thicknesses/IEDs in people with MS, other neurological disorders, and healthy controls using Cirrus HD-OCT. Methods: 509 participants underwent Cirrus HD-OCT, acquiring two macular and optic disc scans per eye within each session. Scans meeting OSCAR-IB quality control criteria were included in final analyses (959 eyes), with no clinical/demographic exclusions (reflecting a real-world clinical setting). Reliability was assessed using coefficients of variation (COVs), intraclass correlation coefficients (ICCs), and Bland–Altman limits of agreement (LOA). IED consistency was evaluated using difference-in-differences (DiDs) of test–retest measurements. Results: GCIPL demonstrated superior reliability (ICC: 0.998, COV: 0.40%, LOA: −1.29 to 1.35 μm) to pRNFL (ICC: 0.989, COV: 1.18%, LOA: −3.59 to 3.70 μm) thickness. Inter-eye absolute DiDs [pRNFL: 2.00 μm (standard deviation (SD) 1.73); GCIPL: 0.64 μm (SD 0.67)] were lower than IED thresholds proposed for identifying UONI. Conclusions: The excellent reliability of GCIPL and pRNFL thicknesses/IEDs support OCT for identifying UONI to diagnose MS.